BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs
18 October 2022 - 04:00PM
Business Wire
Companies to Explore Opportunities to
Integrate Biocorp’s Injay® Technology with BD UltraSafePlus™
Passive Needle Guard to Help Biopharmaceutical Manufacturers
Capture and Transmit Self-Administered Injection Data.
Regulatory News:
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, and Biocorp (Paris:ALCOR), a medical
device and delivery systems manufacturer based in France, today
announced that they have signed an agreement with the aim of using
connected technology to track adherence for self-administered drug
therapies, like biologics.
To support biopharmaceutical companies in their efforts to
improve the adherence and outcomes of injectable drugs, the two
companies will integrate Biocorp’s Injay® technology – a solution
designed to capture and transmit injection events using Near Field
Communication (NFC) technology – to the BD UltraSafe Plus™ Passive
Needle Guard used with prefillable syringes.
“Connected drug delivery devices play an important role in
helping biopharmaceutical manufacturers understand and track key
trends in patient adherence,” said Matthew Schabacker, vice
president and general manager of Advanced Drug Delivery Solutions
at BD. “Our agreement with Biocorp enables us to explore innovative
solutions in this market and further supports BD’s commitment to
smart, connected care, enabling care to transition to alternate
settings and improving chronic disease outcomes — as we combine
Biocorp’s expertise in developing and commercializing connected
drug delivery devices to our existing portfolio of advanced
injection drug delivery systems.”
Biocorp’s Injay® is a simple and cost-effective connected
solution designed to monitor the use of pre-fillable syringes in
clinical studies or routine care. Through NFC technology and
specific sensors to identify the product, it can confirm a complete
injection and easily transfer that information to a smartphone.
“We are very proud to announce this collaboration with BD, a
worldwide leader in pre-filled syringes and safety device market,”
said Eric Dessertenne, CEO of Biocorp. “It shows the leading
position of Biocorp in the field of smart drug delivery devices and
addresses an unmet need in the market today.”
The increased prevalence of self-administered therapies for
chronic diseases coupled with the pervasiveness of digital
technologies in everyone’s life open new opportunities to improve
outcomes and experience for patients and to increase the ability to
monitor medication adherence.
The global connected drug delivery market is expected to grow at
double digit growth rates1 over the next decade – fueled by the
transition from acute care settings to home care and the increased
prevalence of self-administered therapies. Today, BD is a world
leader in supplying prefillable syringes and safety systems to the
biopharmaceutical industry – with approximately 70 percent of the
top 100 biopharmaceutical companies using BD devices, and more than
one billion BD UltraSafe™ units2 sold since 2010 being used to
administer over 40 different drugs.3
About BD
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 75,000 employees have a passion and
commitment to help enhance the safety and efficiency of clinicians'
care delivery process, enable laboratory scientists to accurately
detect disease and advance researchers' capabilities to develop the
next generation of diagnostics and therapeutics. BD has a presence
in virtually every country and partners with organizations around
the world to address some of the most challenging global health
issues. By working in close collaboration with customers, BD can
help enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. For more information on
BD, please visit bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
About Biocorp
Recognized for its expertise in the development and manufacture
of medical devices and delivery systems, BIOCORP has today acquired
a leading position in the connected medical device market thanks to
Mallya. This smart sensor for insulin injection pens allows
reliable monitoring of injected doses and thus offers better
compliance in the treatment of patients with diabetes. Available
for sale from 2020, Mallya spearheads BIOCORP's product portfolio
of innovative connected solutions. The company has 75 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 –
ALCOR). For more information, please visit www.biocorpsys.com.
1 Grandview Research CDDD Market, Data Bridge Market Research
Global CDDD Market 2 As of 2020 3 Drug products approved with BD
UltraSafe™ solutions. Includes both BD UltraSafe Passive™ and BD
UltraSafe Plus™ passive needle guards
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221017006035/en/
BD Media: Trey Hollern
Director, Public Relations 862.284.8629 trey.hollern@bd.com
Investors: Francesca DeMartino SVP,
Head of Investor Relations 201.847.5743
Francesca.demartino@bd.com
BIOCORP Sylvaine Dessard Marketing & Communication
Director rp@biocorp.fr
Bruno ARABIAN barabian@ulysse-communication.com +33 (0)6 87 88
47 26
Biocorp (EU:ALCOR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Biocorp (EU:ALCOR)
Historical Stock Chart
From Mar 2023 to Mar 2024